Fatigue News and Research

RSS

Australia's TGA grants market authorisation for Pierre Fabre Médicament's milnacipran to treat fibromyalgia

The Therapeutic Goods Administration (TGA), Australia's regulatory body for therapeutic products, granted Pierre Fabre Médicament's milnacipran market authorisation for the treatment of fibromyalgia.

21 Nov 2011

Understanding causes of TMJ dysfunction critical to a wellness and drugless approach to care

Understanding the relationship between proper function of the upper cervical spine, cranial bones and temporal-mandibular joint dysfunction (or TMJ dysfunction) is critical to a wellness and drugless approach to care.

19 Nov 2011

Fatigue, poor sleep may jeopardize patient and provider safety in EMS setting

Fatigue and poor sleep quality, which affect many emergency medical services (EMS) workers, are linked to higher reported rates of injuries, medical errors and safety-compromising behaviors, according to a study by University of Pittsburgh researchers that is now available online in Prehospital Emergency Care and appearing in the January-March 2012 print edition.

18 Nov 2011

ACR special issue focuses on assessing adult pain

Assessment of patient outcomes allows physicians and researchers to measure the success or failure of diagnostics and treatments that patients receive. One set of measurement tools focuses on assessing adult pain and is included in a special issue of Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), providing physicians and researchers with a single resource of 250 patient outcomes measurements in rheumatology.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

Exercise may help fibromyalgia: Study

A new study shows that fibromyalgia patients who stopped taking medication but exercised regularly for six weeks reported improved memory function and less pain. While the finding is encouraging, it does not suggest a potential change in clinical care for fibromyalgia patients, the study authors stressed.

15 Nov 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Study uses fMRI to assess changes in brain after exercise intervention

Areas of the brain responsible for pain processing and cognitive performance changed in fibromyalgia patients who exercised following a medication holiday, say researchers from Georgetown University Medical Center. They say the changes indicate brain functioning is more streamlined after an exercise intervention because less of the brain-s resources is devoted to processing bothersome fibromyalgia perceptions such as pain.

14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Sleep problems may increase risk of fibromyalgia among women

Researchers from Norway have uncovered an association between sleep problems and increased risk of fibromyalgia in women.

14 Nov 2011

Scientists suppress NCoR1 protein and create mighty mice

A team of researchers at EPFL, the University of Lausanne and the Salk Institute created super strong, marathon mice and nematodes by reducing the function of a natural inhibitor, suggesting treatments for age-related or genetically caused muscle degeneration are within reach.

11 Nov 2011

Conference highlights advances in evidence-based integrative therapies for cancer

Today the Society for Integrative Oncology highlighted top research findings presented at the Eighth International Conference this week in Cleveland, Ohio. More than 80 abstracts will be presented at the annual meeting, which will be keynoted by National Institutes of Health Director, Francis Collins, MD, PhD.

11 Nov 2011

Link between physical activity, sedentary behavior and sleep in teens

Earlier research has had similar findings, but this is the first large, nationally representative study to connect physical activity, sedentary behavior and sleep in high school students, explained Kathryn Foti, M.P.H., a health scientist at the Centers for Disease Control and Prevention's (CDC) Division of Adolescent and School Health and lead author of the paper.

11 Nov 2011

Encouraging interim results from daclatasvir Phase IIb study in genotype 1 and 4 HCV patients

Bristol-Myers Squibb Company today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events.

9 Nov 2011

Five-year results from Abbott's HUMIRA ATLAS study on ankylosing spondylitis

Abbott today announced five-year results from the open-label extension of the ATLAS study, which evaluated the long-term impact of treatment with HUMIRA (adalimumab) on disease activity, including spinal mobility in patients with active ankylosing spondylitis.

8 Nov 2011

Conway to deploy PatientKeeper's physician healthcare information systems

PatientKeeper, Inc., the leading provider of physician healthcare information systems, today announced that Conway Medical Center has purchased PatientKeeper's suite of advanced clinical applications to automate physician workflow and drive physician adoption of healthcare information technology at their 210-bed hospital located near Myrtle Beach, South Carolina.

7 Nov 2011

Tibotec to present results of TMC435 phase 2b study on HCV at AASLD 2011

Tibotec Pharmaceuticals (Tibotec), one of the Janssen (Janssen) Pharmaceutical Companies, today will present results of the final analysis of PILLAR, a phase 2b study of the investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 in treatment-naïve patients with chronic genotype 1 HCV, as part of a late-breaker oral presentation at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, CA, USA.

7 Nov 2011